Terminated PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT01355302

E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer

An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer

Sponsor: Eisai Inc.

Conditions Advanced or Metastatic Solid Tumors Previously Untreated Gastric Cancer

Interventions E7050 capecitabine cisplatin

Updated 9 times since 2017 Last updated: Apr 7, 2017 Started: Nov 30, 2011 Primary completion: Apr 30, 2013 Completion: Jul 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sites not recruiting

Other terminated trials from Eisai Inc.

More terminations from Eisai Inc.

Other Advanced or Metastatic Solid Tumors trials with similar outcome

Browse all Advanced or Metastatic Solid Tumors trials

A PHASE1/PHASE2 clinical study on Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer, this trial is terminated or withdrawn. The trial is conducted by Eisai Inc. and has accumulated 9 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE1_PHASE2
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE1_PHASE2

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1_PHASE2
May 2017 — Jun 2018 [monthly]

Terminated PHASE1_PHASE2
Feb 2017 — May 2017 [monthly]

Terminated PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1_PHASE2

First recorded

Nov 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eisai Inc.
Quintiles, Inc.

Data source: Eisai Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Chapell Hill, United States , Chelyabinsk, Russia , Chicago, United States , Detroit, United States , Dnipropetrovsk, Ukraine , Donetsk, Ukraine , Durham, United States , Kyiv, Ukraine , London, United Kingdom and 6 more locations